To include your compound in the COVID-19 Resource Center, submit it here.

Sitaxsentan: Phase IIb/III

In the 12-week, double-blind Phase IIb/III STRIDE trial, 300 mg of sitaxsentan gave a significant improvement in predicted peak VO2 from

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE